Table 1.
Prognostic significance of syndecan-1 in relation to its cellular localization.
| Stromal | Soluble | Cell Surface | References | |
|---|---|---|---|---|
| syndecan-1 | syndecan-1 | syndecan-1 | ||
| Intrathoracic cancers | ||||
| Lung | Unfavorable | Favorable | [91, 123, 124, 133, 134] | |
| Mesothelioma | Unfavorable | Favorable | [124, 135] | |
|
| ||||
| Skin cancers | ||||
| Basal cell carcinoma | Favorable | [136] | ||
| Squamous cell carcinoma (oral and cutaneous) | Favorable | Favorable | [94, 137] | |
|
| ||||
| Head and neck cancers | ||||
| Head and neck | Unfavorable | Favorable | [129, 138–140] | |
| Laryngeal, hypopharynx | Unfavorable | [141] | ||
| Nasopharyngeal | Inconclusive∗ | [142, 143] | ||
|
| ||||
| Gastrointestinal cancers | ||||
| Gastric | Unfavorable | Favorable | [144–147] | |
| Colorectal | Unfavorable | Inconclusive∗ | [127, 128, 148, 149] | |
| Hepatocellular | Favorable | [150] | ||
| Pancreatic | Unfavorable | [151] | ||
|
| ||||
| Breast cancer | ||||
| Breast cancer | Inconclusive∗ | Inconclusive∗ | [131, 152–157] | |
|
| ||||
| Urogenital cancers | ||||
| Cervical | Favorable | [158] | ||
| Ovarial | Unfavorable | Unfavorable | [159] | |
| Endometrial | Unfavorable | Inconclusive∗ | [126, 160] | |
| Prostate | Unfavorable | Inconclusive∗ | [93, 125, 161] | |
| Bladder | Unfavorable | Unfavorable | Favorable | [162, 163] |
| Urothelial | Unfavorable | [164] | ||
|
| ||||
| Hematological malignancies | ||||
| Myeloma | Unfavorable | [165–168] | ||
| Hodgkin's lymphoma | Unfavorable | [169] | ||
|
| ||||
| Other cancers | ||||
| Thyroid | Unfavorable | Unfavorable | [130] | |
| Liposarcoma | Unfavorable | [170] | ||
∗ denotes inconclusive results, where different studies show opposite prognosis.